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Human complement factor B is the crucial catalytic compo-
nent of the C3 convertase enzyme that activates the alternative
pathway of complement-mediated immunity. Although a serine
protease in its own right, factor B circulates in human serum as
an inactive zymogen and there is a crystal structure only for the
inactive state of factor B and various fragments. To provide
greater insight to the catalytic function and properties of fac-
tor B, we have used short para-nitroanilide derivatives of 4-
to 15-residue peptides as substrates to profile the catalytic
properties of factor B. Among factors found to influence cat-
alytic activity of factor B was an unusual dependence on pH.
Non-physiological alkaline conditions strongly promoted sub-
strate cleavage by factor B, consistent with a pH-accessible con-
formation of the enzyme that may be critical for catalytic func-
tion. Small N-terminal extensions to conventional hexapeptide
para-nitroanilide substrates significantly increased catalytic
activity of factor B, which wasmore selective for its cleavage site
than trypsin. The new chromogenic assay enabled optimiza-
tion of catalysis conditions, the profiling of different sub-
strate sequences, and the development of the first reversible
and competitive substrate-based inhibitor of factor B. The
inhibitor was also shown to prevent in vitro formation of C3a
from C3 by factor B, by synthetic and by natural C3 conver-
tase of the alternative complement activation pathway, and to
block formation of membrane attack complex. The availabil-
ity of a reversible substrate-based inhibitor that could stabi-
lize the active conformation of factor B, in conjunction with a
pH-promoted higher processing activity, may offer a new ave-
nue to obtain crystal structures of factor B and C3 convertase
in an active conformation.
Factor B (B) is a crucial component of the innate immune
system, contributing to the formation of a multicomponent
complement protease C3 convertase (C3bBb) that plays a vital
role in triggering complement-mediated immune responses to
infection and injury (1, 2). Factor B circulates in human serum
in an inactive zymogen conformation (1, 2), itself consisting of a
three-complement control protein (CCP) domain, a von Will-
ebrand factor type A (vWFA)2 module, and a serine protease
domain (Fig. 1). Following binding to C3b, factor B is recog-
nized and hydrolyzed between its CCP and vWFA domains by
factor D, leading to formation of the heterodimer complex
C3bBb, the C3 convertase of the complement alternative
pathway.
Recent crystal structures of the serine protease domain (3),
the vWFA module (4), a modified Bb (5), and factor B itself (6)
have revealed that factor B adopts a chymotrypsin-like foldwith
several novel structural motifs. The catalytic triad residues
Asp551, His501, and Ser674 were in a typical active conformation
found in serine proteases; however, residues that normally
define the oxyanion hole produced an unusual conformation
because of the inward orientation of the carbonyl group of
Arg671 hydrogen-bonded to the NH group of Ser674 to form a
310 helix. This abnormal conformation is believed to be respon-
sible for the zymogen property of factor B under physiological
conditions. The vWFA domain contains an integrin-like
MIDAS (metal ion-dependent adhesion site) motif that may
serve as a binding site for C3b, consistent with the requirement
for Mg2 to form C3bBb from C3 and factor B.
In its native state, factor B has negligible proteolytic activity
on its native substrate protein C3 at physiological pH. When
factor B is bound to C3b and processed by factor D (Fig. 2), the
resulting C3bBb is an efficient and specific serine protease that
cleaves C3 (Km 5.9 M, kcat 1.78 s1) (7). However, upon irre-
versible dissociation, the catalytic domain Bb retains only
diminished (1%) proteolytic activity (8). Despite having an inac-
tive zymogen-like oxyanion conformation, factor B still exhibits
some esterolytic activity against thiobenzyl ester substrates,
including dipeptide analogue Cbz-KR-SBzl, for which the high-
est catalytic efficiency has been reported (kcat/Km 1370M1s1)
(9). Under the same conditions, the isolated Bb domain dis-
played slightly improved catalytic efficiency (kcat/Km 2320
M1s1) due mainly to a lower Km (0.58 versus 1.19 mM). Nei-
ther a factor B-specific assay nor any other substrates have been
reported to date.
Recently, our understanding about the precise role of factor
B in the alternative pathway has expanded through the avail-
ability of gene-depleted mice and monoclonal antibodies (10,
11). There is now growing evidence for an essential role of fac-
tor B in activating the alternative complement pathway inmod-
els of numerous inflammatory diseases (10, 11). Studies using
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wild type, factor B-deficient, or C4-deficient mice in conjunc-
tion with specific anti-factor B monoclonal antibodies have
demonstrated that factor B is critical for allergen-induced
development of airway hyper-responsiveness and inflamma-
tion (11, 12). Factor B deficiency has been reported to amelio-
rate K/BxN serum transfer and collagen-induced models of
rheumatoid arthritis (11, 13). As an indispensable component
of the alternative pathway, factor B has also been implicated in
inflammatory disorders of renal tissue injury (11, 14–16). A
functionally intact alternative, but not classical, complement
pathway was demonstrated to be crucial in renal ischemia-
reperfusion injury, whereas both pathways are required for
development of intestinal ischemia/reperfusion tissue damage
(11, 17–19). Brain ischemia results in complement activation
with C3 levels that are significantly higher in infarcted than in
non-injured brain (20). Both C3 and neuronal ischemia are
attenuated by intravenous immunoglobulin (IgG) that scav-
enges complement fragments (20). The alternative pathway
also proved to be important in kidney inflammation such as
lupus nephritis and type II membranoproliferative glomerulo-
nephritis (11, 21–25). When factor B was neutralized with a
specific monoclonal antibody, mice were significantly pro-
tected from complement activation and fetal loss stimulated by
antiphospholipid antibody (11, 26). Human complement
receptor of the immunoglobulin superfamily (CRIg), a factor
B-specific inhibitor, also reversed inflammation and bone loss
in two mouse models of arthritis (27).
To date, no specific smallmolecule inhibitors of factor Bhave
been described, and only a few moderately active and non-se-
lective inhibitors of C3/C5 convertase are known, such as
FUT175 (IC50, 4 M) (28) and the allosteric inhibitor compsta-
tin (IC50, 12M) (29). The former compound (nafamostat) is in
clinical use in Japan to treat acute pancreatitis and glomerulo-
nephritis, but it also inhibits a wide range of targets, including
many human serine proteases (30, 31). A major problem in
developing inhibitors of C3 convertase has been the difficulty in
readily measuring C3 convertase activity. Additionally, sub-
strate-based analogues have so far failed to inhibit processing of
C3 byC3 convertase (30–32). The availability of smallmolecule
inhibitors of factor B and C3 convertase could be valuable for
probing physiological and patho-physiological roles of factor B
in vivo and for evaluating these enzymes as possible therapeutic
targets for new complement-based drugs. Here we report the
development of a valuable new rapid chromogenic assay for
measuring factor B activity in vitro, the discovery of some
important and unexpected molecular and catalytic properties
of factor B for substrate processing, and the discovery of the
first substrate-based inhibitor of factor B that also inhibits C3
convertase. These results provide a valuable beginning to better
understanding the activity of factor B and C3 convertase, to a
more robust method of screening potential inhibitors, and to
the rational development of potent and selective inhibitors of
C3 cleavage resulting from complement activation.
EXPERIMENTAL PROCEDURES
Materials—Factor B, factor D, C3, and cobra venom factor
were obtained from Calbiochem, or Quidel. Protein molecular
weight markers for gels were purchased from Sigma. Fmoc
(N-(9-fluorenyl)methoxycarbonyl)-protected amino acids were
from Novabiochem. Gel ingredients, casting apparatus, and
resolving chamber (Mini-PROTEAN Tetra CellTM) were from
Bio-Rad. Proteins were visualized using colloidal Coomassie
Brilliant Blue staining solution. All other chemical reagents
were analytical grade from Sigma.
Para-nitroanilide (pNA) Substrate Synthesis—pNA sub-
strates were synthesized according to the general method of
Abbenante et al. (33) and characterized by analytical high per-
formance liquid chromatography andmass andNMR spectros-
copy (see supplemental material).
Enzymatic Characterization and Substrate Analysis—Factor
B was assayed against short peptide substrates corresponding
to the relevant cleavage site in the endogenous substrate C3 but
with a chromogenic pNA group in the P1-position at the C
terminus. Cleavage of pNA from the peptides by factor B pro-
duces a yellow color that enables continuous monitoring of
absorbance changes at the wavelength 405 nm. The assay was
conducted in a 96-well plate, with a final reaction volume of 150
l containing factor B at concentrations of 25, 50, or 75 nM
FIGURE 1. Schematic representation of factor B showing components
CCP1–3 (three-complement control proteins), vWFA (von Willebrand
factor type A), and SP (serine protease).
FIGURE 2. Complement activation paths. Activation of the classical/lectin
pathways results in assembly of C4b2a whereas activation of the alternative
pathway leads to formation of C3bBb, both of whichmay be C3 convertases.
The cleavage product C3b of either pathway can bind to factor B, generating
more C3bB and amplifying the alternative pathway of complement
activation.
Enzymatic Properties of Human Complement Factor B
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using semi-optimized conditions (100 mM glycine-HCl buffer,
pH 9.5, 154 mM NaCl, 1% Me2SO). Eight different substrate
concentrations, each in duplicate, were used for determining
kinetic constants. After preincubation in separate wells (5 min,
37 °C), catalysis was initiated by mixing substrate with enzyme
buffer solution with automatic shaking for 5 s. The optical den-
sity was measured at 405 nm every 30–60 s for 30 to 120 min
(depending on activity) in a Fluostar Optima (BMG Labtech)
reader, and the average change in millioptical density/min was
calculated. Kinetic parameters were calculated from weighted
nonlinear regression of the initial velocities as a function of the
eight substrate concentrations using GraphPad Prism 4 soft-
ware. The parameters kcat, Km, and kcat/Km were calculated
assumingMichaelis-Menten equilibrium kinetics, vVmax[S]/
([S]  Km). Duplicate measurements were taken for each data
point, and means S.E. are reported.
RESULTS
Factor B Cleaves C3 at Alkaline pH—Factor B circulates in
serum intact and is known to be inactive against its native sub-
strate C3 at pH 7.4. We now report that factor B alone does in
fact cleave C3 fairly rapidly but only at higher pH (pH 9) and
with moderate efficiency. For example, Fig. 3 shows a mini-gel
analysis indicating that incubating factor BwithC3 in buffers of
varying pH 8 at 37 °C for 3 h results in formation of a protein
corresponding to C3a (lane 3), verified by a commercial sample
([MH] 9084 Da). A band for factor B at 97 kDa remains
intact at all pH values examined (lanes 4–7), but in the presence
of C3 another band at100 kDa is also produced at pH 9.3 and
10.2 (lanes 5–7), corresponding to the cleavage product of the
chain of C3. These new protein bands are identical to those
obtained (Fig. 3) from cleavage (pH 7.4, 37 °C) of C3 by C3
convertase (lane 8) generated by mixing cobra venom factor,
factor B, and factor D (32). The C3 samples used (98%) (Cal-
biochem) have an apparentmolecularmass of 180 kDa, appear-
ing on SDS-PAGE gels as a single band or two bands under
non-reducing or reducing conditions, respectively. The ability
of factor B to process C3 at alkaline pH is independent of the
concentrations of Na, Mg2, or the metal ion scavenger
EDTA (supplemental Fig. S2, a and b).
Because these results indicated that hydrolytic activity of
factor B proportionally increased with pH, we also examined
the ability of factor B alone to hydrolyze synthetic peptides
of varying length, corresponding to the native cleavage
sequence in C3, at pH 7.4 or 9.5. We found that factor B
hydrolyzed the 15-residue synthetic peptide substrate Ac-
QHARASHLGLAR2SNL-NH2, corresponding to the native
sequence at the cleavage site in C3, significantly faster at pH 9.5
than at pH 7.4. The enzyme only recognized the native cleavage
site LAR2SNL with no hydrolysis detected at the non-native
Ac-QHAR2AS site. By contrast, trypsin cleaved the same pep-
tide at both sites (data not shown). Similar observations were
made for the corresponding but shorter 10-residue peptide
Ac-ARASHLGLAR-pNA (1), in which the prime side tripep-
tide component was replaced by the chromogenic para-ni-
troaniline (Fig. 4). At pH 9.5, factor B only catalyzed hydrol-
ysis at the native cleavage site LAR2pNA, with negligible
hydrolysis detected even after 24 h at the non-native
Ac-AR2ASH site. Trypsin cleaved the same peptide at both
sites at pH 8 (Fig. 4).
Development of a Chromogenic Assay for Factor B—Toward
the development of a rapid chromogenic assay for monitoring
factor B activity in vitro, a library of systematically shortened
pNA substrates was prepared to examine effects of peptide
sequence and length. For comparison, we also included Cbz-
KR-pNA, which has the non-prime site identical to that of the
best reported thiobenzyl ester substrate (9). Preliminary results
indicated that octapeptide Ac-ASHLGLAR-pNA (3) was one of
the best substrates, so we used it to optimize the conditions of
the chromogenic assay described below.
Effect of pH on Enzymatic Activity—The catalytic activity of
factor B against octapeptide Ac-ASHLGLAR-pNA (3) was
FIGURE3.FactorB cleavesC3athighpH.C3 (10g) and factor B (4g)were
incubated at 37 °C in 32 l of buffer at the indicated pH (154 mM NaCl in all
buffers) for 3 h. a, top region of 7%gel, loading of 2.5gof C3/well. b, bottom
region of 12% gel, loading of 5.0g of C3/well. Lane 1, molecular massmark-
ers (SigmaMarker; Sigma). Lane 2, C3 showing  (112 kDa) and  (68 kDa)
chains. Lane 3, factor B (top) and C3a (bottom). Lanes 4–7, C3 plus factor B (pH
7.4 (PBS), 8.3 (Tris), 9.3 (glycine), 10.2 (glycine) showingpH-dependent forma-
tion of C3a after 3 h at 37 °C. Lane 8, C3 plus C3 convertase (pre-formed from
cobra venom factor, factor B, and factor D in PBS). Full gels of panels a and
b are available in supplemental Fig. S1, a and b, respectively.
FIGURE4.HydrolysisofdecapeptideAc-ARASHLGLAR-pNA(1)by factorB
or trypsin. Substrate (1 mM) was incubated with factor B (50 nM) at pH 9.5 or
trypsin (50 nM) at pH 8.0, 37 °C for the indicated time periods. The samples
were filtered through a size exclusion filter with 10-kDa cut-off and analyzed
byanalytical highperformance liquid chromatography. Identities of products
were confirmed by liquid chromatography-mass spectrometry.
Enzymatic Properties of Human Complement Factor B
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investigated over a wide pH range, using a variety of buffers
(Tris-HCl, pH 7.5–8.50; glycine-HCl, pH 9.00–10.50; piperi-
dine-HCl, pH 10.75–11.5). The optimal pH for most rapid
processing of this substrate by factor Bwas10.5 (Fig. 5). Auto-
hydrolysis of this substrate was negligible at or below pH11.5 in
the absence of factor B, but the catalytic activity decreased
abruptly above pH 10.5, presumably due to denaturation of fac-
tor B. The effect of pH on the catalytic activity of factor B was
independent of Na (154 mM NaCl, Fig. 5; 0 mM NaCl, supple-
mental Fig. S3).
Effect of Divalent Cations, Ion Strength, and Other Additives—
Effects of diluents were probed at pH 9.5. Although the vWFA
domain of factor B contains an integrin-likeMIDAS (metal ion-
dependent adhesion site)motif that could binddivalent cations,
neither calcium (10 mM), magnesium (10 mM), nor the divalent
cation-sequestering agent EDTA (10 mM) detectably influ-
enced the activity of factor B in vitro. Similarly, neither varia-
tion of ionic strength (NaCl 0–250 mM) nor addition of bovine
serum albumin (1%), polyethylene glycol (1%), or glycerol (10%)
had any effect on the substrate-processing ability of factor B.
Under the semi-optimal conditions (pH 9.5, 100 mM glycine-
HCl buffer, 154 mM NaCl), we found that factor B exhibited
classic Michaelis-Menten kinetics against the pNA substrate 3,
with kcat 10.19  0.19 s1, Km 2.19  0.08 mM, and kcat/Km
4666 253 M1s1 (Fig. 6).
Effects of Substrate Length—A number of pNA peptide sub-
strates were synthesized, ranging from 4 to 10 amino acids cor-
responding to the native cleavage sequence of C3. BecauseCbz-
KR-SBzl has been reported to be the best thioester substrate for
factor B (9), its corresponding pNA analogue, Cbz-KR-pNA,
was also prepared for comparison.
Among eight putative substrates examined (Fig. 7), the 8-
and 7-residue pNA peptides (3 and 4) proved to be the best
substrates, with initial velocity of 0.17–0.19 Ms1 (50 nM fac-
tor B, pH 9.5, (substrate) 1mM). The Cbz-KR-pNA substrate
displayed10-fold lower initial velocity under identical condi-
tions. Km and kcat values for selected substrates are recorded in
Table 1. Heptapeptide substrate 4 (Km 8.4 mM, kcat 1 s1,
kcat/Km 8315) was processedmost efficiently by factor B.When
this substrate was examined using factor B obtained from a
different supplier (Quidel), comparable catalytic efficiency was
observed (Km 1.15 0.21mM, kcat 9.1 0.6s1, kcat/Km 8258
2070 M1s1).
Effect of the 7th Residue in Substrates—The 7th residue serine
in the heptapeptide substrate Ac-SHLGLAR-pNA (4) was var-
ied to probe substrate requirements at this position. Large
hydrophobic or negatively charged side chains at this position
significantly decreased hydrolysis by factor B (Fig. 8). Of the
FIGURE 5. Dependence on pH of hydrolysis of Ac-ASHLGLAR-pNA (3) by
factor B. Ac-ASHLGLAR-pNA (1 mM) was incubated with 75 nM factor B at pH
7.5, 8.5, 9.0, 9.25, 9.5, 9.75, 10.0, 10.25, 10.5, 10.75, 11.0, 11.25, and 11.5. Initial
velocity (M/s) was calculated as amount of free pNA released from increase
in millioptical density/s (at 405 nm). All buffers contained 154 mM NaCl.
FIGURE 6. Hydrolysis of octapeptide substrate (3). Ac-ASHLGLAR-pNA (3)
for different concentrations of factor B enzyme (25, 50, 75 nM) and pNA sub-
strate (0.1, 0.2, 0.4, 0.8, 1.2, 1.6, 2.0, 3.0 mM) at pH 9.5, 37 °C. Initial velocity
(M/s) was calculated as amount of free pNA released from increase in mil-
lioptical density/s (at 405 nm).
FIGURE 7. Effect of substrate length on factor B catalysis. Substrates are Ac-
ARASHLGLAR-pNA (1, 10-mer), Ac-RASHLGLAR-pNA (2, 9-mer), Ac-ASHLGLAR-
pNA (3, 8-mer), Ac-SHLGLAR-pNA (4, 7-mer), Ac-HLGLAR-pNA (6-mer), Ac-
LGLAR-pNA (5-mer), Ac-GLAR-pNA (4-mer), and Cbz-KR-pNA. Substrates (1
mM) were incubated with 50 nM factor B in glycine-HCl buffer, pH 9.5, at
37 °C. Change in optical density at 405 nm in the first 5–10minwas used to
calculate the initial velocities.
TABLE 1
Kinetic parameters for pNA peptide substrates
Km and kcat were determined using initial velocities for selected 7–10-residue sub-
strates at concentrations 0.2, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 mM.
Substrate kcat Km kcat/Km
s1 mM
Ac-ARASHLGLAR-pNA (1) 12.6a 12.4a 1016a
Ac-RASHLGLAR-pNA (2) 12.8a 15.8a 810a
Ac-ASHLGLAR-pNA (3) 10.19 0.19 2.19 0.08 4666 253
Ac-SHLGLAR-pNA (4) 8.38 1.4 1.05 0.14 8315 2458
Ac-AHLGLAR-pNA (5) 8.20 0.02 2.84 0.05 2884 54
Ac-KHLGLAR-pNA (6) 8.25 0.22 2.79 0.5 3045 467
a Values estimated from a single experiment at substrate concentrations of 0.1, 0.2,
0.4, 0.8, 1.2, 1.6, 2.0, 3.0 mM.
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small number of heptapeptide substrates investigated (Fig. 8),
compound 4with Ser at position 7 proved to be the best. A serine
mimetic, isoxazole-5-carbonyl, was poorly tolerated, while small
side chains (Ala) or positively charged moieties (Lys, Dapa (dia-
minopropionic acid)) caused small decreases in initial velocities
(Fig. 8).
Substrate-based Inhibitor of Factor B andC3Convertase—To
convert substrate 4 to a putative inhibitor, the pNAmoiety was
replaced by an aldehyde group to furnish compound 7 (Ac-
SHLGLAR-H). This compound proved to be a moderately
potent inhibitor of factor B (IC50 19 M, Fig. 9), blocking the
cleavage of C3 in a concentration-dependentmanner under the
same assay conditions (Fig. 11, supplemental Fig. S4, a and b).
In this inhibitor, the aldehyde functional group is capable of
forming a reversible covalent bond with the catalytic Ser side
chain, resulting in a tetrahedral configuration that mimics the
transition state.
Compound 7 is a reversible and competitive inhibitor of fac-
tor B, since increasing concentrations of substrate 4 overcame
the inhibition of factor B caused by 100M 7 (Fig. 10). Cleavage
of the native substrate C3 to C3a andC3b by factor B at pH 10.2
was also inhibited by aldehyde 7 in a concentration-dependent
manner (Fig. 11). Because factor B also provides the crucial
catalytic unit within C3 convertase of the alternative pathway,
compound 7was also examined for inhibition of C3 convertase.
Cleavage of C3 by C3 convertase generated either from a com-
bination of cobra venom factor, factor B, and factor D (CVF.Bb;
Fig. 12 and supplemental Fig. S5, a and b) or from human C3,
factor B, and factor D (hC3bBb, supplemental Fig. 6, a and b) in
the presence of Mg2 was indeed inhibited by aldehyde 7 in a
dose-dependent manner. Under the same conditions, general
serine protease inhibitors leupeptin or phenylmethylsulfonyl
fluoride at 1-mM concentrations did not inhibit C3 cleavage
(supplemental Fig. S6, a and b).
DISCUSSION
Factor B is currently considered to be an inactive zymogen
serine protease involved in the alternative pathway of comple-
FIGURE 8. Initial velocities for factor B processing of heptapeptide-pNA
substrates. Substrates varied in the 7th residue: Ac-AHLGLAR-pNA (5, Ala),
Ac-LHLGLAR-pNA (Leu), Ac-FHLGLAR-pNA (Phe), Ac-DHLGLAR-pNA (Asp), Ac-
KHLGLAR-pNA (6, Lys), Ac-Isox-HLGLAR-pNA (isoxazole-5-carboxylic acid,
Isox), Ac-Dapa-HLGLAR-pNA (L-diaminopropionic acid, Dapa), Ac-SHLGLAR-
pNA (4, Ser). Substrates (1mM) were incubatedwith 50 nM factor B in glycine-
HCl buffer, pH 9.5, at 37 °C. Change in optical density at 405 nm in the first
5–10 min was used to calculate initial velocities.
FIGURE 9. Dose-dependent inhibition of factor B by compound 7. Condi-
tions were 100 mM glycine-HCl buffer, pH 9.5, 37 °C, 50 nM factor B, 0.5 mM
pNA substrate 4, eleven concentrations (from1 M to 1 mM) of 7. Positive
control was buffer alone (not shown).
FIGURE 10. Effect of substrate concentration on inhibition by 7. Substrate
4 at concentrations of 0.5, 2.5, 5, or 10 mM was incubated with 50 nM factor B
in the presence of 100 M inhibitor 7, 100 mM glycine-HCl buffer, pH 9.5, at
37 °C. Increases in absorbance were monitored at  405 nm.
FIGURE 11. Compound 7 inhibits cleavage of C3 by factor B in a concen-
tration-dependent manner. C3 (10 g) and factor B (4 g) were incubated
at 37 °C in 32 l of 100 mM glycine-HCl buffer, pH 10.2, with various concen-
trations of inhibitor 7. a, top region of 7% gel, loading of 2.5 g of C3/well.
b, bottom region of 12% gel, loading of 5.0 g of C3/well. Lane 1, molecular
mass markers (SigmaMarker; Sigma). Lane 2, C3a. Lane 3, C3 showing  (112
kDa) and  (68 kDa) chains. Lane 4, factor B. Lanes 5–9, C3, factor B plus buffer
(lane 5) or inhibitor (lanes 6–9, 0.01, 0.1, 0.25, 0.5 mM compound 7) showing
inhibitionofC3 cleavage toC3aafter 3hat 37 °C. Full gels ofpanels a andb are
available in supplemental Fig. S4, a and b, respectively.
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ment activation (1, 2). Recent studies using knock-outmice and
a specific antibody have demonstrated important contributions
from factor B to a number of inflammatory disorders (10, 11),
such as airway hyper-responsiveness (12), lupus nephritis (34),
and antiphospholipid syndrome (26, 35), and have provided
insights to the role of factor B in complement activation via the
alternative pathway. The new data from those studies suggest
that factor B may be a potential therapeutic target in its own
right.Moreover, selective inhibitors of factor B (none is known)
could potentially be valuable newmolecular probes for investi-
gating the biology of factor B and its homologue C3 convertase,
as well as providing clues to the development of novel thera-
peutics that might regulate the alternative pathway of comple-
ment activation (10, 11). To date, only a couple of weakly potent
and non-selective inhibitors of C3 convertase are known (28,
29), but they are not substrate analogues and have been of little
use for understanding C3 cleavage relevant to complement
activation. No protease inhibitors for factor B are known, and
there is no chromogenic assay available for monitoring enzyme
activity for either factor B or C3 convertase in vitro.
Factor B is known to be inactive against its native substrate
C3 at pH 7.4 (1, 2), and this may be the reason why factor B
function has not been heavily studied. Experiments reported
here have shown that factor B alone can hydrolyze C3 under
mild to strong alkaline conditions. Importantly, the cleavage
products from factor B-mediated hydrolysis of C3 at pH 10.2
are identical to those produced by cobra venom factor-contain-
ing C3 convertase at pH 7.4, as demonstrated by gel analysis
(Fig. 3). The significance of these new findings of pH-induced
activation of factor Bmay be important in understanding catal-
ysis by factor B. The structure of the active conformation of
factor B remains elusive, as it is stable only in complex with C3b
or theC3b surrogate, cobra venom factor.On the basis of recent
NMR and x-ray crystal structures for an inactive state of factor
B, it has been proposed that activation of factor B likely pro-
ceeds through multiple conformational changes (1, 2, 6, 36)
induced by binding to C3b and then through cleavage by factor
D (1, 2, 6, 36).
On the basis of our results it is conceivable that, at alkaline
pH, factor B changes its protonation state and adopts an active
conformation that can more effectively recognize and cleave
C3. Other serine proteases are known to be activated under
alkaline conditions. For example, NS2B-NS3 serine proteases
from flaviviruses (e.g.West Nile, dengue, yellow fever) (37–42)
become substantially active in vitro only at alkaline pH (10.5).
Those enzymes, like factor B, are thought to interact with other
protein domains and to deposit on membrane surfaces under
native conditions for proteolytic processing. Human kallikrein
6 has been reported to exhibit significantly higher catalytic
activity at pH 9.0 than at pH 7.5 (43); the basis for such pH
dependence is not well understood at present.
The catalytic activity of factor B against small pNA substrates
was also found here to exhibit a strong pH dependence. The
hydrolysis of pNA substrates by factor B followed classic
Michaelis-Menten kinetics. The magnitude of kinetic parame-
ters (Table 1) for our pNA substrates supports the idea that
factor B adopts an active conformation at higher pH, since all
substrates are processed quite fast kcat (8 s1), comparable
with the catalytic hydrolysis of C3 by C3 convertase (kcat 1.78
s1). On the other hand, kcat/Km values for the pNA substrates
are only modest (Table 1), due to a high Km (low mM). This
suggests a much lower substrate affinity for the pNA substrates
than for C3 (Km 5.9 M for C3 processing by C3 convertase).
Strikingly, factor B prefers longer substrates than other ser-
ine proteases.We found that pNA substrateswith short peptide
sequences (7 residues) were very poor substrates for factor B,
unlike other serine proteases that tend to recognize shorter
segments of polypeptide substrates and inhibitor analogues (30,
44, 45). Aminomethyl courmarin substrates of 6 residues
have been reported not to be processed effectively by C3 con-
vertase (32). Substrates with 7 or 8 residues, in contrast to
shorter peptides, were found here to be readily processed by
factor B. Trypsin and thrombin, which recognize shorter sub-
strate sequences, still process the heptapeptide AcSHLGLAR-
pNA and are inhibited by the corresponding AcSHLGLAR-al-
dehyde (supplemental Fig. S8, a and b). However, trypsin can
process AcARASHLGLARSNL-NH2, corresponding to the
native sequence at the cleavage site in C3, at both the AR2A
and AR2S sites, whereas factor B only cleaved at the AR2S
site and only effectively in sequenceswith 7 ormore residues on
theN-terminal side. The crystal structure of factor B in its inac-
tive state (3, 6) shows shallow putative binding pockets at S1-S6
in the enzyme, consistent with the need for some additional
binding residues attached to hexapeptide substrates. However,
the unusual requirement of small P7 (Ser) and P8 (Ala) residues
for enhancement of substrate processing was surprising. Using
NMR spectroscopy, we did not detect any conformational
changes in water going from 6- to 7- residue peptides, which
were both random coil structures (3JNH-CH coupling constants
for 6-mer were 6.8, 5.8, 7.5, 5.9, 6.6, 6.8 Hz and for 7-mer were
6.7, 8.0, 5.9, 7.2, 5.9, 6.1 Hz), so it would appear that the sub-
FIGURE 12. Compound 7 inhibits cleavage of C3 by C3 convertase
(CVF.Bb) in a concentration-dependent manner. a, top region of 7% gel,
loading of 2.5g of C3/well. b, bottom region of 12% gel, loading of 5.0g of
C3/well. C3 convertase was generated by incubating 12 g of cobra venom
factor, 8 g of factor B, and 0.2 g of factor D in 100 l of PBS, pH 7.4, con-
taining 1mMMgCl2 for 1 h at 37 °C, and then 100l of PBS, pH 7.4, containing
20 mM EDTA was added. C3 (10 g) and the C3 convertase (6 l) were incu-
bated at 37 °C for 30 min in final 32 l of PBS, pH 7.4, with buffer or various
inhibitor concentrations. Lane 1, molecular mass markers (SigmaMarker;
Sigma). Lane 2, C3 showing  (112 kDa) and  (68 kDa) chains. Lane 3, C3a.
Lanes 4–8, C3, C3 convertase plus buffer (lane 4) or inhibitor (lanes 5–8, 0.01,
0.1, 0.25, 0.5 mM) showing inhibition of C3a formation after 37 °C for 30 min.
Full gels of panels a and b are available in supplemental Fig. S5, a and
b, respectively.
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strate extensions cause higher receptor affinity (note lower Km
values) because of their side chains rather than a conforma-
tional change to the substrate.
The substrate-processing results may reflect that enzymatic
processing of C3 is only slightly dependent on affinity or selec-
tivity for substrate residues immediately surrounding the cleav-
age site. Indeed, the sequence of C3 at the cleavage site is not
greatly different from that of substrates for other serine pro-
teases. Instead, the selectivity for processing of C3 during com-
plement activation is probably heavily influenced by the multi-
ple domains of C3 convertase, evolved for selective recognition
of this particular substrate under different complement activa-
tion conditions produced by different environmental stimuli. It
has been estimated that 40% of proteases are multidomain
enzymes (46), and many of those appear to use the appended
domains for selective substrate recognition.
It has been proposed that C3 binds C3 convertase through
several docking sites on theC3b component of C3bBb complex,
which in turn interacts with Bb to induce the active conforma-
tion (5). In a simple model of binding between C3 and Bb, the
positively charged loop 2 of Bb could possibly interact with the
negative charges on the anchor region and/or MG8 of C3 (47).
The proposed interactions may confer the relatively high
implied affinity of C3 (Km 5.9 M) for the C3bBb complex, and
thus only C3 convertase (but not Bb) can bind to C3 efficiently
for hydrolysis to occur. Consistent with this hypothesis, Bb
requires the presence of divalent cations (Mg2 or Ni2) to
cleave C3, although with only 1% activity of factor B (8).
Until now, rational design of substrate-based C3 convertase
inhibitors such as-ketoheterocycles has reportedly failed (32),
possibly because of the limitation of low affinity of the quite
short peptide sequences examined to date. Despite the low
affinity of substrate 4 for factor B, replacing the pNA moiety
with an aldehyde C-terminal cap afforded a moderately
active factor B inhibitor 7 (IC50 19 M). This compound also
inhibits the cleavage of C3 at high pH by factor B or at pH 7.4
by C3 convertase (generated from cobra venom factor, factor
B, and factor D or from human C3, factor B, and factor D) in
a concentration-dependent manner (Figs. 11 and 12, and
supplemental Figs. S4-S6). Furthermore, aldehyde 7 is able
to inhibit downstream formation of membrane attack com-
plex to a comparable extent via the alternative pathway (sup-
plemental Fig. S7).
Access to the active conformation of factor B could be quite
valuable for better understanding of the molecular mechanism
bywhichC3 convertase carries out its catalytic function and for
devising more effective therapeutic strategies to intervene in
prolonged complement activation. The novel results presented
above suggest that factor B may adopt an active enzyme con-
formation at alkaline pH and, in complex with a reversible sub-
strate-based aldehyde inhibitor, could potentially present the
first opportunity to obtain crystal structures for factor B andC3
convertase in their catalytically active forms. The chromogenic
assay reported here is quite robust and allows for rapid screen-
ing of compounds as putative inhibitors of factor B and C3
convertase. Compound 7, designed and evaluated using this
assay, inhibits cleavage of C3 by both factor B and C3 conver-
tase in a concentration-dependent manner. This indicates that
the inhibitor is competitive and reversible and thus directed at
the catalytic substrate-binding active site of both enzymes.
These results for this new assay, developed for factor B but also
validated here for native and synthetic forms of C3 convertase
from the alternative pathway, suggest that potent substrate-
based inhibitors of these serine proteases may now be achieva-
ble. Development of such inhibitors into even more potent,
selective, and more drug-like compounds may facilitate ratio-
nal intervention in the alternative pathway of complement acti-
vation and the blockade of membrane attack complex
formation.
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Le et al Supplementary Material S1 
 
 
Figure S1a: pH Dependence of C3 cleavage by Factor B (7% gel analysis).  
C3 (10 µg) and factor B (4 µg) were incubated at 37°C in 32 µL buffer at the indicated pH for 3h. 
Loading of 2.5 µg C3/well. Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: C3 
showing alpha (112kDa) and beta (68 kDa) chains. Lane 3: factor B. Lanes 4-7: C3 plus Factor B (pH 
7.4, 8.3, 9.3, 10.2) showing pH-dependent formation of C3a after 3h at 37°C. Lane 8: C3 plus C3 
convertase (pre-formed from cobra venom factor, factor B and factor D). All buffers contain 154 mM 
NaCl. 
 
 
 
Figure S1b: pH Dependence of C3 cleavage by Factor B (12% gel analysis). C3 (10 µg) and factor 
B (4 µg) were incubated at 37°C in 32 µL buffer at the indicated pH for 3h. Loading of 5.0 µg C3/well. 
Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: C3 showing alpha (112kDa) and beta 
(68 kDa) chains. Lane 3: C3a. Lanes 4-7: C3 plus Factor B (pH 7.4, 8.3, 9.3, 10.2) showing pH-
dependent formation of C3a after 3h at 37°C. Lane 8: C3 plus C3 convertase (pre-formed from cobra 
venom factor, factor B and factor D). All buffers contain 154 mM NaCl. 
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Figure S2a: Metal Ion Independence of C3 cleavage by Factor B (7% gel analysis). C3 (10 µg) and 
factor B (4 µg) were incubated at 37°C in 32 µL of various buffer (all at pH 10.3) for 3h. Loading of 
2.5 µg C3/well. Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: factor B. Lane 3: C3 
showing alpha (112kDa) and beta (68 kDa) chains. Lanes 4-7: C3 (2.5 µg) and factor B (1 µg). Lane 4: 
Glycine buffer pH 10.3 plus 154mM NaCl, lane 5: Glycine buffer pH 10.3, no added NaCl, lane 6: 
Glycine buffer pH 10.3 plus 5mM MgCl2 and no added NaCl, lane 7: Glycine buffer pH 10.3 plus 
5mM EDTA and no added NaCl. 
 
 
Figure S2b: Metal Ion Independence of C3 cleavage by Factor B  (12% gel analysis). C3 (10 µg) 
and factor B (4 µg) were incubated at 37°C in 32 µL of various buffer (all at pH 10.3) for 3h. Loading 
of 5.0 µg C3/well. Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: factor B. Lane 3: 
C3 showing alpha (112kDa) and beta (68 kDa) chains. Lanes 4-7: C3 (5.0 µg) and factor B (2 µg). 
Lane 4: Glycine buffer pH 10.3 plus 154mM NaCl, lane 5: Glycine buffer pH 10.3, and no added 
NaCl, lane 6: Glycine buffer pH 10.3 plus 2.5mM MgCl2 and no added NaCl, lane 7: Glycine buffer 
pH 10.3 plus 2.5mM EDTA and no added NaCl. 
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Figure S3: Initial velocity for hydrolysis of Ac-ASHLGLAR-pNA (3) by factor B at varying pH 
without Na+. Ac-ASHLGLAR-pNA (1mM) was incubated with 75nM factor B at pH 7.5, 8.5, 9.0, 
9.25, 9.5, 9.75, 10.0, 10.25, 10.5, 10.75, 11.0, 11.25 and 11.5. Initial velocity (mM/s) was calculated as 
amount of free pNA released from increase in millioptical density/second (at 405 nm). All buffers 
contained no added NaCl. 
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Figure S4a: Compound 7 inhibits cleavage of C3 by factor B in a concentration dependent 
manner (7% gel analysis). C3 (10 µg) and factor B (4 µg) were incubated at 37°C in 32 µL, 100mM 
glycine-HCl buffer, pH 10.2 with various concentrations of inhibitor 7. Loading of 2.5 µg C3/well. 
Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: C3a. Lane 3: C3 showing alpha 
(112kDa) and beta (68 kDa) chains. Lane 4: factor B. Lanes 5-9: C3, Factor B plus buffer (lane 5) or 
inhibitor (lanes 6-9: 0.01, 0.1, 0.25, 0.5 mM compound 7) showing inhibition of C3 cleavage to C3a 
after 3h at 37°C. All buffers contain 154 mM NaCl. 
 
Figure S4b: Compound 7 inhibits cleavage of C3 by factor B in a concentration dependent 
manner (12% gel analysis). C3 (10 µg) and factor B (4 µg) were incubated at 37°C in 32 µL, 100mM 
glycine-HCl buffer, pH 10.2 with various concentrations of inhibitor 7. Loading of 5.0 µg C3/well. 
Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: C3a. Lane 3: C3 showing alpha 
(112kDa) and beta (68 kDa) chains. Lane 4: factor B. Lanes 5-9: C3, Factor B plus buffer (lane 5) or 
inhibitor (lanes 6-9: 0.01, 0.1, 0.25, 0.5 mM compound 7) showing inhibition of C3 cleavage to C3a 
after 3h at 37°C. All buffers contain 154 mM NaCl. 
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Figure S5a: Compound 7 inhibits cleavage of C3 by C3 convertase (CVF.Bb) in a concentration 
dependent manner (7% gel analysis). Loading of 2.5 µg C3/well. C3 convertase was generated by 
incubating 12µg of cobra venom factor, 8µg of factor B and 0.2 µg of factor D in 100 µL PBS (pH 7.4) 
containing 1mM MgCl2 for 1 h at 37°C, then was added 100µL PBS (pH 7.4) containing 20mM 
EDTA. C3 (10 µg) and the C3 convertase (6 µl) were incubated at 37°C for 30 min. in final 32 µL PBS 
(pH 7.4) with buffer or various inhibitors concentrations. Lane 1: molecular mass markers 
(SigmaMarker, Sigma). Lane 2:.C3 showing alpha (112kDa) and beta (68 kDa) chains Lane 3: C3a. 
Lanes 4-8: C3, C3 convertase plus buffer (lane 4) or inhibitor (lanes 5-8: 0.01, 0.1, 0.25, 0.5 mM) 
showing inhibition of C3a formation after 37°C for 30 min. 
 
Figure S5b: Compound 7 inhibits cleavage of C3 by C3 convertase (CVF.Bb) in a concentration 
dependent manner (12% gel analysis). Loading of 5.0 µg C3/well. C3 convertase was generated by 
incubating 12µg of cobra venom factor, 8µg of factor B and 0.2 µg of factor D in 100 µL PBS (pH 7.4) 
containing 1mM MgCl2 for 1 h at 37°C, then was added 100µL PBS (pH 7.4) containing 20mM 
EDTA. C3 (10 µg) and the C3 convertase (6 µl) were incubated at 37°C for 30 min. in final 32 µL PBS 
(pH 7.4) with buffer or various inhibitors concentrations. Lane 1: molecular mass markers 
(SigmaMarker, Sigma). Lane 2: C3 showing alpha (112kDa) and beta (68 kDa) chains. Lane 3: C3a. 
Lanes 4-8: C3, C3 convertase plus buffer (lane 4) or inhibitor (lanes 5-8: 0.01, 0.1, 0.25, 0.5 mM) 
showing inhibition of C3a formation after 37°C for 30 min. 
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Figure S6a: Compound 7 (vs. leupeptin and PMSF negative controls) inhibits cleavage of C3 by 
native C3 convertase (human C3bBb) in a concentration dependent manner (7% gel analysis). C3 
(10 µg), factor B (0.5 µg) and factor D (0.05 µg) were incubated at 37°C in 32 µL, PBS containing 
1mM MgCl2, pH 7.4 with various concentrations of inhibitor 7, leupeptin or PMSF. Loading of 2.5 µg 
C3/well. Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: factor B. Lane 3: C3 
showing alpha (112kDa) and beta (68 kDa) chains. Lane 4: C3a, Lanes 5-10: C3, factor B and factor D 
buffer (lane 5) or inhibitor (lanes 6-8: 1.0, 0.5, 0.25 mM compound 7, lane 9: 1.0mM of leupeptin, lane 
10: 1,0 mM of PMSF) showing inhibition of C3 cleavage to C3a after 30 minutes at 37°C. All buffers 
contain 154 mM NaCl and 1mM MgCl2. 
 
Figure S6b: Compound 7 (vs. leupeptin and PMSF negative controls) inhibits cleavage of C3 by 
native C3 convertase (human C3bBb) in a concentration dependent manner (12% gel analysis). 
C3 (10 µg), factor B (0.5 µg) and factor D (0.05 µg) were incubated at 37°C in 32 µL, PBS containing 
1mM MgCl2, pH 7.4 with various concentrations of inhibitor 7, leupeptin or PMSF. Loading of 5 µg 
C3/well. Lane 1: molecular mass markers (SigmaMarker, Sigma). Lane 2: factor B. Lane 3: C3 
showing alpha (112kDa) and beta (68 kDa) chains. Lane 4: C3a, Lanes 5-10: C3, factor B and factor D 
buffer (lane 5) or inhibitor (lanes 6-8: 1.0, 0.5, 0.25 mM compound 7, lane 9: 1.0mM of leupeptin, lane 
10: 1,0 mM of PMSF) showing inhibition of C3 cleavage to C3a after 30 minutes at 37°C. All buffers 
contain 154 mM NaCl and 1mM MgCl2. 
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Assay procedure for the determination of IC50 for aldehyde inhibitor 
AcSHLGLAR-H Vs alternative pathway 
 
The assay kit is available from EURO-DIAGNOSTICA (Medeon, SE-205 12 Malmo, 
Sweden. Catalogue #: COMPL 300).  
The protocol is modified from the manufacture’s instruction to allow IC50 
determination. 
Principle of the assay: 
The assay based on the principle of the haemolytic assay for the complement cascade. 
Briefly, wells of the microtitre strips are coated with specific activators of each 
classical, alternative or lectin pathways. Human serum are first diluted with buffers 
containing specific blockers of the other pathways, ensuring that only the desired 
pathway is activated in each well. 
After activation, the resulting MAC is detected with alkaline phosphatase labeled 
antibodies specific to the neoantigen expressed during MAC formation. The amount 
of the antibodies are quantified based on extent of substrate cleavage by the 
phosphatase. 
 
Assay protocol: 
Stock solutions of inhibitors were prepared in PBS (pH 7.4) in a three-fold serial 
dilutions starting from the highest concentration of 36.45mM. 
 
Dilution of serum (Sigma, Cat. # H4522): 
Alternative pathway: 264µL of the supplied alternative pathway diluent was mixed 
with 30µL of human serum, and 6µL of the inhibitor stock solutions or PBS (positive 
control). The solutions were incubated at room temperature for 30 minutes. 
 
MAC formation 
To each well specific for the alternative pathway was added 100µL of the above-
diluted serum in duplicate. The wells were incubated at 37°C for 1hr with lid. 
After incubation the wells were emptied and washed three times with 300 µL of the 
supplied washing buffer using multi channel pipette. After the last wash, the wells 
were emptied by tapping the strips on absorbent tissues.  
 
MAC quantification: 
100µL of supplied conjugate solution was added to the washed wells and allowed to 
incubate at room temperature for 30 minutes. The wells were washed as described 
above. To each well was then added 100µL of substrate solution and absorbance of 
the wells were monitored at 405nm on a microplate reader at 25°C. The increase of 
absorbance after 30-minute incubation was calculated and taken as proportional to the 
quantity of the antibodies.The final concentrations of the inhibitors were: 729µM, 
243µM, 81µM, 9µM, 3µM, 1µM, and 0µM. 
IC50 for AcSHLGLAR-H Vs alternative pathway is 15±5µM 
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Figure S7. Inhibition of MAC formation by compound 7 via the alternative pathway. 
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Assay procedure for the determination of IC50 for aldehyde inhibitor 
AcSHLGLAR-H Vs Thrombin and Trypsin 
 
 
Buffer For Both Assays : 10mM Hepes, 10mM Tris, 150mM NaCl,    
   0.1%PEG, pH=7.4 
 
Substrate :  The substrate used was in both cases was AcSHLGLAR-pNA. A 100mM 
solution of the substrate in DMSO was prepared and 0.75 µL of this solution was added to 
each well. Final concentration in each well is 0.5mM or 500µM. 
 
Enzyme concentration for Trypsin: Commercially supplied trypsin (1 mM) was diluted 
100X in buffer (to a concentration of 10uM) and 2µL of this solution was used for each well. 
Final concentration in each well is 133nM.  
 
Enzyme concentration for Thrombin: Commercially supplied thrombin (100U/ml) was 
diluted 2X in buffer (50U/mL) and 10µL of this solution was used for each well. Final 
amount of enzyme in each well is 0.5U. 
 
Inhibitor AcSHLGLAR-H: For trypsin a 2X serial dilution of inhibitor was used starting 
from 2mM solution of the aldehyde in buffer. The highest concentration of inhibitor used in 
the assay was 26.6µM. Eleven different descending concentrations of inhibitor were used. 
For thrombin, a 2X serial dilution of inhibitor was used starting from 50mM solution of the 
aldehyde in buffer. The highest concentration of inhibitor in the assay was 666µM. Eleven 
different descending concentrations of inhibitor were used. 
 
Total volume of each well is 150µL and reaction was monitored at 405nm at 37°C. 
 
The assays were performed in duplicate (thrombin) and triplicate (trypsin) – see Fig. 8 below.  
IC50 for AcSHLGLAR-H Vs Thrombin is 24±1 µM 
IC50 for AcSHLGLAR-H Vs Trypsin is 716±35 nM 
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Figure S8a : Inhibition of trypsin mediated cleavage of AcSHLGLAR-pNA by compound 7.  
 
 
Figure S8b : Inhibition of thrombin mediated cleavage of AcSHLGLAR-pNA by compound 7.  
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NMR Spectroscopy. Samples for NMR analysis were prepared by dissolving the 
compounds (1-3mg) in 0.5 mL H2O/D2O (9/1) and 1D 1H-NMR spectra were recorded on a 
Bruker Avance DRX-600 spectrometer. Spectra were processed using Topspin (Bruker, 
Germany) software.  
 
 
Fig. S9a. 1D 1H-NMR spectra of Ac-ARASHLGLAR-pNA (1) 
 
 
Fig. S9b. 1D 1H-NMR spectra of Ac-RASHLGLAR-pNA (2) 
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Fig. S9c. 1D 1H-NMR spectra of Ac-ASHLGLAR-pNA (3) 
 
 
Fig. S9d. 1D 1H-NMR spectra of Ac-SHLGLAR-pNA (4) 
 
 
Fig. S9e. 1D 1H-NMR spectra of Ac-HLGLAR-pNA  
Le et al Supplementary Material S13 
 
Fig. S9f. 1D 1H-NMR spectra of Ac-LGLAR-pNA  
 
 
Fig. S9g. 1D 1H-NMR spectra of Ac-GLAR-pNA  
 
 
Fig. S9h. 1D 1H-NMR spectra of Cbz-KR-pNA in H2O/D2O at 25°C.  
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In water, Cbz-KR-pNA exists as a mixture of two conformers in the ratio of ~2.5/1. In 
DMSO, at 25°C the ratio change to about 8.7/1, and at 45°C only one conformer was 
observed. 
 
 
Fig. S9i. 1D 1H-NMR spectra of Cbz-KR-pNA in DMSO d6 at 25°C 
 
Fig. S9j. 1D 1H-NMR spectra of Cbz-KR-pNA in DMSO d6 at 45°C 
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Fig. S9k. 1D 1H-NMR spectra of Ac-AHLGLAR-pNA (5) 
 
 
Fig. S9m. 1D 1H-NMR spectra of Ac-LHLGLAR-pNA  
 
 
Fig. S9n. 1D 1H-NMR spectra of Ac-FHLGLAR-pNA  
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Fig. S9o. 1D 1H-NMR spectra of Ac-DHLGLAR-pNA  
 
 
Fig. S9p. 1D 1H-NMR spectra of Ac-KHLGLAR-pNA (6) 
 
 
Fig. S9q. 1D 1H-NMR spectra of Isox-HLGLAR-pNA  
Le et al Supplementary Material S17 
 
Fig. S9r. 1D 1H-NMR spectra of Ac-Dapa-HLGLAR-pNA 
 
 
 
Fig. S9s. 1D 1H-NMR spectra of Ac-SHLGLAR-H (7) 
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